Loading quotes...
Forecast
The analysts' average price target is €98.32 (-12.99%). The median is €98.32 (-12.99%).
| Buy |
3 |
| Hold |
5 |
| Sell |
0 |
News Go to news feed
Mesa Laboratories misses Q1 revenue forecast, improves margins and cash flow
Mesa Laboratories reported revenue of $60.1 million (+1%) in the first fiscal quarter, missing the Wall Street forecast of $61.49 million by about 2.3%. Despite the modest revenue shortfall, gross margin rose to 64.9%, adjusted operating income climbed to $15.0 million (+16.5%), and operating cash flow jumped to $14.7 million. By segment, BPD and calibration solutions grew, while the largest segment, SDC, recorded an organic decline due to supply issues. Management plans to provide the annual outlook at the next report in November and is focusing investments on higher-growth, higher-return business areas. » More on de.investing.com
Mesa Laboratories approves quarterly dividend of $0.16
The board of Mesa Laboratories has announced a quarterly dividend of $0.16 per common share, representing a yield of 0.61%. The dividend will be paid on September 15, 2026 to shareholders of record at the close of trading on August 31, 2026. Mesa Laboratories manufactures life‑science instruments and quality-control solutions; the stock is up 35% year-to-date and is trading at $103.80. » More on de.investing.com
Mesa Laboratories to report results on May 27, 2026, analysts expect a significant jump in earnings
Mesa Laboratories will release quarterly results on May 27, 2026. Two analysts expect EPS of $2.09 on average after -$1.31 a year earlier; the revenue estimate from three analysts is $65.2 million (+4.96% versus $62.1 million). For the past fiscal year, two analysts forecast EPS of $9.07 (previous year -$0.36) and three analysts estimate annual revenue at $250.6 million versus $241.0 million a year earlier. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 52.69m | 4.31% |
| Gross profit | 34.18m | 23.99% |
| Net profit | 2.48m | 38.37% |
| EBITDA | 10.83m | 15.83% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €610.06m |
Number of shares | 5.6m |
52-week high/low | €129.02 - €62.13 |
Dividend yield | 0.50% |
Dividends TTM | €0.55 |
Beta | 1.05 |
P/E ratio | 141.83 |
PEG ratio | -0.38 |
P/B ratio | 3.66 |
P/S ratio | 2.73 |
Company profile
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
| Name | MESA LABS INC. |
| CEO | Siddhartha C. Kadia |
| Headquarters | Lakewood,
co USA |
| Website | |
| Sector | Industrials |
| Industry | Electrical Equipment |
| IPO | 29/02/1984 |
| Employees | 717 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | MLAB |
Frankfurt | MLI.F |
Düsseldorf | MLI.DU |
München | MLI.MU |